✦ LIBER ✦

Downstream effects of first line bevacizumab (bev) on outcomes after recurrence in advanced ovarian cancer

✍ Scribed by E. Bishop; L. Perry; R. Previs; A. Alvarez-Secord; K. Moore

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

NICE guidance on bevacizumab in combinat

✍ Dyer, Matthew; Richardson, Joanna; Robertson, Janet; Adam, Jane 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 52 KB

NICE guidance on bevacizumab in combinat

✍ Pinilla-Dominguez, Pilar; Richardson, Joanna; Robertson, Janet; Adam, Jane 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 52 KB

9112 POSTER AVAPERL1 (MO22089) – Interim

✍ Ahn, M.; Gervais, R.; Mezger, J.; Reck, M.; Orlov, S.; Burgers, J.A.; Bearz, A.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

9003 ORAL Biomarker Analysis in BO21015,

✍ Mok, T.; Gorbunova, V.; Juhasz, E.; Szima, B.; Burdaeva, O.; Yu, C.J.; Delmar, P 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB